Literature DB >> 34900771

Association of ACE I/D and PAI-1 4G/5G polymorphisms with susceptibility to type 2 diabetes mellitus.

Somaye Miri1, Mohammad Hasan Sheikhha2, Seyed Alireza Dastgheib3, Seyed Amir Shaker4, Hossein Neamatzadeh2,5.   

Abstract

BACKGROUND: A number of studies were carried out to assess the association of angiotensin I converting enzyme (ACE) I/D and plasminogen activator inhibitor-1 (PAI-1-1) 4G/5G polymorphisms with susceptibility to type 2 diabetes mellitus (T2DM). However, there are a few studies in Iranian patients with T2DM. Here, we tested for an association of ACE I/D and PAI-1 4G/5G polymorphisms with T2DM risk.
METHODS: One hundred-eighteen patients with T2DM and 125 healthy subjects were participates in this study. The ACE I/D (rs4340) and PAI-1 4G/5G (rs1799889) polymorphisms was genotyped by conventional and PCR-RFLP assays, receptively. The associations was evaluated by calculating the odds ratio (OR) and 95% confidence interval (95% CI).
RESULTS: The genotype distribution of ACE I/D and PAI-1 4G/5G polymorphisms were not deviated from the Hardy-Weinberg equilibrium in healthy controls. The ACE II, ID, and DD genotype frequencies were 18.6%, 48.3%, and 33.1% in the T2DM patients versus 24.0%, 45.6% and 30.4% in healthy subjects, respectively. The PAI-1 4G/4G, 4G/5G, and 5G/5G genotype frequencies were 16.9%, 51.7%, and 31.4% in cases versus 24.8%, 57.6% and 17.6% in controls, respectively. There is a significant distribution in genotype/allele of PAI-1 4G/4G between cases with T2DM and healthy control, but not for ACE I/D. Moreover, the 5G/5G genotype is significantly (OR = 2.139, CI 95% 1.171-3.907, p = 0.013) increased the risk of T2DM by two folds in the cases than healthy controls.
CONCLUSIONS: Our findings suggest that PAI-1 4G/5G may be likelihood risk factor for the development of T2DM in the Iranian patients. The higher frequency of PAI-1 5G/5G genotype in patients with T2DM revealed that individuals with the 5G allele may be at higher risk of T2DM development than those with 4G. However, there was no significant association between ACE I/D polymorphism and T2DM in our population. Future rigorous, well-designed studies with larger sample should replicate this study to confirm our findings in Iranian T2DM patients. © Springer Nature Switzerland AG 2021.

Entities:  

Keywords:  Angiotensin I Converting Enzyme; Plasminogen Activator Inhibitor-1; Polymorphism; Type 2 Diabetes

Year:  2021        PMID: 34900771      PMCID: PMC8630325          DOI: 10.1007/s40200-021-00839-7

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  42 in total

1.  Angiotensin converting enzyme insertion/deletion (I/D) (rs4646994) and Vegf polymorphism (+405G/C; rs2010963) in type II diabetic patients: Association with the risk of coronary artery disease.

Authors:  Atousa Moradzadegan; Asad Vaisi-Raygani; Abdolrahim Nikzamir; Zohreh Rahimi
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2014-02-06       Impact factor: 1.636

Review 2.  Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications.

Authors:  Mariana Murea; Lijun Ma; Barry I Freedman
Journal:  Rev Diabet Stud       Date:  2012-05-10

3.  The angiotensin-I converting enzyme I/D polymorphism is not associated with type 2 diabetes in individuals undergoing coronary angiography. (The Ludwigshafen Risk and Cardiovascular Health Study).

Authors:  Tanja B Grammer; Wilfried Renner; Sabine von Karger; Bernhard O Boehm; Bernhard R Winkelmann; Winfried Maerz
Journal:  Mol Genet Metab       Date:  2006-06-12       Impact factor: 4.797

4.  Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.

Authors:  I Ezzidi; N Mtiraoui; M Chaieb; M Kacem; T Mahjoub; W Y Almawi
Journal:  Diabetes Metab       Date:  2009-05-05       Impact factor: 6.041

Review 5.  Plasminogen Activator Inhibitor-1 4G/5G Polymorphism Contributes to Osteonecrosis of the Femoral Head Susceptibility: Evidence from a Systematic Review and Meta-analysis.

Authors:  Mohammad R Sobhan; Masoud Mahdinezhad-Yazdi; Mansour Moghimi; Kazem Aghili; Mohammadali Jafari; Masoud Zare-Shehneh; Hossein Neamatzadeh
Journal:  Arch Bone Jt Surg       Date:  2018-11

6.  Association between the Angiotensin-Converting Enzyme (ACE) Genetic Polymorphism and Diabetic Retinopathy-A Meta-Analysis Comprising 10,168 Subjects.

Authors:  Shasha Luo; Chao Shi; Furu Wang; Zhifeng Wu
Journal:  Int J Environ Res Public Health       Date:  2016-11-15       Impact factor: 3.390

Review 7.  Environmental Risk Factors for Developing Type 2 Diabetes Mellitus: A Systematic Review.

Authors:  Tashi Dendup; Xiaoqi Feng; Stephanie Clingan; Thomas Astell-Burt
Journal:  Int J Environ Res Public Health       Date:  2018-01-05       Impact factor: 3.390

8.  Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes.

Authors:  Angli Xue; Yang Wu; Zhihong Zhu; Futao Zhang; Kathryn E Kemper; Zhili Zheng; Loic Yengo; Luke R Lloyd-Jones; Julia Sidorenko; Yeda Wu; Allan F McRae; Peter M Visscher; Jian Zeng; Jian Yang
Journal:  Nat Commun       Date:  2018-07-27       Impact factor: 14.919

9.  Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism Is Not Responsible for Antihypertensive Therapy Induced New Onset of Type 2 Diabetes in Essential Hypertension.

Authors:  Vikas Jhawat; Sumeet Gupta; Bimal K Agarwal; Partha Roy; Vipin Saini
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-01-23

Review 10.  Proportion and mortality of Iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with COVID-19: a meta-analysis.

Authors:  Hamid Mirjalili; Seyed Alireza Dastgheib; Seyed Hossein Shaker; Reza Bahrami; Mahta Mazaheri; Seyed Mohamad Hossein Sadr-Bafghi; Jalal Sadeghizadeh-Yazdi; Hossein Neamatzadeh
Journal:  J Diabetes Metab Disord       Date:  2021-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.